Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial

Area of Science:

• Respiratory Medicine
• Clinical Pharmacology

Background:

• Tiotropium is an established anticholinergic bronchodilator for COPD, improving lung function and reducing exacerbations.
• Stable bronchiectasis with airflow limitation is a chronic respiratory condition requiring effective management strategies.

Purpose of the Study:

• To investigate the efficacy of tiotropium in reducing pulmonary exacerbations in patients with stable bronchiectasis and airflow limitation.
• To assess the impact of tiotropium on lung function parameters in this patient population.

Main Methods:

• A randomized, double-blind, two-period crossover trial involving adult patients with stable bronchiectasis.
• Patients received tiotropium 18 μg via HandiHaler or placebo daily for six months, followed by a four-week washout period.
• The primary endpoint was the rate of event-based exacerbations; lung function was a secondary outcome.

Main Results:

• No significant difference in exacerbation rates was observed between tiotropium (2.17/year) and placebo (2.27/year) groups (rate ratio 0.96, p=0.77).
• Tiotropium significantly improved forced expiratory volume in 1 second (FEV1) by 58 mL compared to placebo (p=0.002).
• Adverse events were comparable between the tiotropium and placebo treatments.

Conclusions:

• Six months of tiotropium treatment via HandiHaler improved lung function in patients with stable bronchiectasis and airflow limitation.
• Tiotropium did not significantly reduce the frequency of exacerbations in this patient group.
• Further research is warranted to elucidate the clinical implications and significance of these findings in bronchiectasis management.